New treatment offers hope for endometrial cancer patients
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its “primary endpoints” of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer. The TroFuse-005 trial is the first global Phase 3 trial to “demonstrate statistically significant … Read more